ABSTRACT: Inspired by the preferential, allosteric binding of RAPTA-T and auranofin to the nucleosome core particle , we describe the design and synthesis of a series of heterobimetallic ruthenium(II)−gold(I) complexes with varying spacer lengths ranging from four to eight polyethylene glycol units. Evaluation of their cytotoxicity reveals IC 50 values in the low micromolar range against cisplatin sensitive and resistant human ovarian carcinoma (A2780, A2780cisR) and nontumoral human embryonic kidney (HEK293) cell lines. Binding studies monitored via mass spectrometry revealed an affinity for histidine residues on a fragment of the amyloid β-protein (residues 1−16, employed as a model system), which is in accordance with the binding sites of parent drugs, RAPTA-C and auranofin, to the nucleosome core particle.
■ INTRODUCTION
Understanding and controlling the targets of metal-based drugs remains of great importance in the development of selective drugs.
1,2 Ruthenium-based drugs possess a plethora of targets ranging from proteins to DNA, 3, 4 and yet directing these complexes toward a desirable target remains challenging. A degree of control can be established in ruthenium(II)-arene complexes by exchanging the bidentate ethylenediamine ligand of [(η 6 -p-cymene)Ru (en)]PF 6 (where en = ethylene diamine) (RAED-C) for the compact, water-soluble PTA ligand of [(η 6 -p-cymene)RuCl 2 (PTA)] (where PTA = 1,3,5-triaza-7-phosphaadamantane) (RAPTA-C, Figure 1 ), which directs the complex preferentially toward histone protein binding sites on the nucleosome over those of DNA. 5 Furthermore, DNA binding of RAED-C can be enhanced by substituting the pcymene arene with the more hydrophobic 5,8,9,10-tetrahydroanthracene (THA), resulting in the intercalation of DNA and bimodal binding on naked DNA. 6 On the other hand, RAPTA-C and [Ru(η 6 -toluene)(PTA)Cl 2 ] (RAPTA-T), which differ only by an iso-propyl group, form specific and identical adducts on histone H2A and H2B histone dimers of the nucleosome core. 7 Notably, a series of binuclear ruthenium-(II)-arene complexes are able to cross-link these binding sites, inducing a state of irreversible condensed chromatin, resulting in apoptosis. 8 The binding of RAPTA-T 9 at these sites, consisting of two glutamic acid residues (RU1) and a glutamic acid and histidine residue (RU2), causes a series of structural changes in the nucleosome core that induces a kink in the long α-helix of the H2A histone protein. This structural alteration opens up a binding site for auranofin, a gold(I) drug of the structure (1-thio-β-D-glucopyranose-2,3,4,6-tetraacetato-S)-(triethylphosphine)gold(I) (Figure 1 ), approved for the treatment of rheumatoid arthritis, 10 that is inaccessible prior to the binding of the RAPTA-T. A synergy between the two drugs was discovered where RAPTA-T appears to sensitize the cells to auranofin, resulting in a beneficial increase in tumor cell cytotoxicity and a threefold increase in auranofin chromatin adducts. 11 Heterobimetallic complexes have emerged as a promising family of complexes that can combine the attributes and targets of two metals within one structure. 12−18 As well as the capacity to possess markedly higher activities than the parent drugs alone, 19 heterometallic drugs have a myriad of potential applications. Numerous heterometallic complexes possessing photophysical properties have been considered for cellular imaging, 20, 21 as trackable probes, 22, 23 and as drug carriers for cytotoxic complexes. 24−26 Ferrocenyl and titanocene complexes are particularly versatile building blocks for heterometallic complexes due to their facile functionalization and favorable redox properties 27−34 Received: November 1, 2018 Published: February 7, 2019 However, heterometallic complexes combining cisplatin-, RAPTA-, and auranofin-type drugs have been scarcely explored. Ruthenium−gold and ruthenium−platinum species have been shown to possess cytotoxicities comparable to cisplatin against HeLa cells. 35 A platinum(II)−gold(I) complex was encapsulated within a ferritin cage with the aim of enhancing its selectivity; however, the complex was unstable with the gold(I) complex binding to the protein and platinum remaining in the bulk, decreasing the efficacy of the agent. 36 A ruthenium(II)−platinum(IV) prodrug possessing high cytotoxicity against cisplatin resistant cells was also able to inhibit cell migration. 37 The combination of RAPTA complexes, which possess a general low toxicity and antimetastatic properties, 2 and auranofin, which is highly cytotoxic with anti-inflammatory properties, 38 offers great potential. Few heterometallic complexes based on ruthenium(II)-arene compounds and auranofin have been reported. [(η 6 -p-Cymene)RuCl 2 (μ-dppm)Au(IMes)]ClO 4 (RANCE-1, Figure 1 ), where dppm = diphenylphophanylmethyl(diphenyl) phosphane and IMes = 1,3-bis(2,4,6-trimethylphenyl)imidazole-2-ylidene), is a promising heterobimetallic complex exhibiting efficient inhibition of thioredoxin reductase (TrX), vascular endothelial growth factor (VEGF), pan-matrix metalloproteinases (pan-MPP), and pan-cathepsin. When compared to auranofin, RANCE-1 presents similar antiproliferative activity against renal cancer cell line (Caki-1) and improved inhibition of VEGF, pan-MMP, and pan-cathepsin. 39 Replacing the auranofin-like thiolato-β-D-glucose tetraacetate ligand with a chloride ligand results in a threefold decrease in cytotoxicity against human ovarian carcinoma (A2780) cells. 40 Other examples include [(η 6 -p-cymene)RuCl 2 (μ-dppm)AuCl] (RUAU-1, Figure 1 ) and [(η 6 -p-cymene)RuCl 2 (μ-dppm)Au(S-thiazoline)], which shows that differing the sacrificial ligand coordinated to the gold center does not impact the activity in this case. 41 However, introducing N-heterocyclic carbene ligands to the gold center in cationic ruthenium(II)−gold(I) complexes of the same structure can enhance tumor cell selectivity. 42 Herein, we describe the synthesis, cytotoxicity, and target binding studies of a series of heterobimetallic complexes containing RAPTA-C− and auranofin-like fragments. The design of the complexes aims to preserve the structure of the parent drugs, RAPTA-C and auranofin, as closely as possible while allowing flexibility to enable binding at two different and distal sites. A series of linker lengths was explored to determine the impact of the linker length on the cytotoxicity of the complexes. The ability of the complexes to bind to histidine residues was explored via mass spectrometry using both single amino acids and a fragment of the amyloid β-protein.
■ RESULTS AND DISCUSSION
With the aim of targeting the binding sites of RAPTA-C and auranofin, maintaining the key structural features of the parent drugs is important. However, alterations are required in order to tether the complexes via a flexible linker with the PTA and triethylphosphine ligands, belonging to RAPTA-C and a u r a n o fi n , r e s p e c t i v e l y , b e i n g r e p l a c e d b y 4 -(diphenylphosphosphino)benzoic acid ligands, which provide a functionalizable carboxylic acid moiety and air stability. The labile thio-β-D-glucose-2,3,4,6-tetraacetate ligand of auranofin is replaced with a labile chloride ligand. The p-cymene arene and the two labile chloride ligands present in RAPTA-C were maintained due to the hydrophobic interactions provided by the arene during binding and the vital role of the chlorides in the activation of the complex via aquation. Polyethylene glycol was selected as a suitable linker due to its flexibility and its higher water solubility compared to that of alkyl chains.
As a 4-(diphenylphosphosphino)benzoic acid ligand is coordinated to both the ruthenium(II) and the gold(I) centers, care must be taken to achieve high selectivity in the coupling step. Manipulation of reaction stoichiometry was insufficient to control the monocoordination of either ruthenium or gold to a bis-phosphine ligand. Therefore, monophosphine ligands (1a−1d) were prepared via the e s t er i fi c a t i on r ea c t i on b e tw e e n 1 e q u i v o f 4 -(diphenylphosphosphino)benzoic acid and 1.5 equiv of the appropriate polyethylene glycol chain using N-ethyl-N′-(3-dimethlaminopropyl)carbodiimide hydrochloride (EDCI) as coupling reagent and 4-(dimethylamino)pyridine (DMAP) as base catalyst (Scheme 1). Ligands 1a−1d (Scheme 1) were coordinated to the gold via a freshly prepared gold(I)-tetrahydrothiophene intermediate to yield gold(I) complexes H} NMR spectroscopy. The phosphine ligand coordinated to the ruthenium center produces a characteristic singlet at ca. 25 ppm, whereas the gold-phosphine peak is observed at ca. 33 ppm (cf. ca. −5 ppm for the free ligand), allowing the reactions to be easily m o n i t o r e d . In Vitro Antiproliferative Activity. The antiproliferative activity of 4a−4d was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay against cisplatin sensitive and resistant human ovarian carcinoma (A2780 and A2780cisR) and nontumoral human embryonic kidney (HEK-293) cell lines (Table 1) . 43 Cisplatin, auranofin, and RAPTA-C were tested as controls.
The cytotoxicity of the parent complex, RAPTA-C, is low against a range of cell lines, with an IC 50 > 200 μM against the tested cell lines. Compounds 4a−4d possess IC 50 values in the low micromolar range against all tested cell lines, with values comparable to those of cisplatin and auranofin against the A2780 cell line and to auranofin against the A2780 CisR cell line. Although the compounds overcome cisplatin resistance, they do not show selectivity toward the tumoral cell lines compared to the nontumoral cell lines. Moreover, the length of the PEG linker has negligible impact on the cytotoxicity of the complexes, showing that the cytotoxicity of these complexes is 
1.8 ± 0.6 3.9 ± 0.5 3.5 ± 0.4 cisplatin 1.9 ± 0.4 13.3 ± 1.2 9 ± 0.8 auranofin 44 1.3 ± 0.5 1.5 ± 0.5 1.9 ± 0.6 RAPTA-C >200 >200 >200
a Values are given as the mean ± SD (μM). 50 values of 4.6 ± 0.1 μM (1) and 6.5 ± 0.1 μM (2) versus 8−10 μM for the cationic NHC complexes. 41 RANCE-1 ( Figure 1 ) also presents comparable cytotoxicity to the cationic NHC complexes with an IC 50 of 8.7 ± 0.9 μM against Caki-1 cells, which is around threefold more cytotoxic than cisplatin but threefold less cytotoxic than auranofin against the same cell line. 39 Amino Acid and Peptide Binding Studies. The ability of the heterobimetallic complexes to bind to the amino acid residues present in the RU1, RU2, AU1, and AU1′ binding sites in the nucleosome core particle was assessed using amino acids and a model peptide. In crystallographic studies on the nucleosome core particle, auranofin binds to histidine residues while RAPTA-T binds to both histidine and glutamine residues. 11 Complex 4b was incubated with L-histidine for 2 h in a 1:1 complex−amino acid ratio in unbuffered solution (98% Milli-Q water, 2% DMSO) at 310 K, and the adducts were analyzed by mass spectrometry.
Inorganic Chemistry
45−47 ESI-MS revealed a peak at m/z 894.6949 corresponding to the adduct [4b − 3Cl + 3His + 2K] 2+ , in which dissociation of the three labile chloride ligands and subsequent binding of three histidine residues indicates that both the ruthenium and gold centers bind to histidines.
Peptide binding studies were performed on a fragment of the amyloid β-protein (residues 1−16, H-Asp −OH). Complex 4a was incubated with the 16-mer for 2 h in a 1:3 complex−peptide ratio in unbuffered solution (98% Milli-Q, 2% DMSO) at 310 K. A 1:3 complex−peptide ratio was required to suppress the facile ionization of the gold center that suppresses the signal of peptide complex adducts. ESI-MS revealed 1:1 adducts of 4a and the 1−16 amyloid β-peptide; 1:2 complex−peptides adducts were not observed ( Figure 4 ). The loss of the three labile chloride ligands in the complex indicates that both the ruthenium and gold centers are coordinated to at least one amino acid residue cross-linking the peptide. Complex 4d, possessing the longest linker of the series of PEG 8 , was incubated with the 1−16 amyloid β-peptide under identical conditions. Similarly to 4a, 1:1 complex−peptide adducts were observed, while 1:2 complex−peptide adducts were not found. To obtain further information on the mode of binding in Figure S21 ) was chosen for fragmentation due to its high charge state and intact 4a adduct. Collision induced dissociation (CID), producing predominantly b-and y-type fragments, 48 and electron-transfer dissociation (ETD) fragmentation, which breaks N−C α bonds along the peptide backbone producing c-and z-type fragments, 49 were performed. ETD fragmentation has recently been used to evaluate the binding of dinuclear ruthenium(II)-arene complexes on the amyloid β-peptide where the metal centers were found to bind to histidine residues. 50 The analysis of the fragments produced was performed using an online Apm 2 s application (available on http://www.cheminfo.org/ flavor/mass/index.html), 46, 51 which enabled the identification of both terminal and internal fragments that are otherwise difficult to identify manually.
As both the ruthenium and gold centers can bind to histidine, it is likely that the [peptide + 4a + 5H − 3Cl] 5+ ion represents a mixture of adducts in which the metals interact with His As it is plausible that both the gold and the ruthenium centers could bind to any of the His 6 , His 13 , and His 14 sites, a ruthenium or gold center bound to the His 6 and His 13 residues could be impeding further fragmentation of the peptide-4a adduct. Metalated b-and y-type fragments containing [4a − 3Cl] are also observed in the CID spectrum ( Figure 6) ; however, the smallest fragments found are b 11 * and y 12 * and do not yield much information.
However, the observed unmetalated internal fragments only include one, if any, histidine residues. Fragments c 13 z 8 , c 13 15 and c 12 z 9 , do not contain any histidines residues. This suggests that the histidine residues that are not included in the fragments could be bound to 4a.
In contrast, all the observed metalated CID and ETD internal fragments containing the [4a −3Cl] adducts contain at least one histidine residue ( Figure 7 ). The CID internal fragments b 6 , and His 14 , suggesting that the gold and ruthenium centers are both bound to the fragment via at least one histidine.
Concluding Remarks. A series of heterometallic ruthenium(II)−gold(I) complexes inspired by the preferential binding of RAPTA-T and auranofin in the nucleosome core particle was synthesized with different lengths of linkers ranging from 4 to 8 PEG units. They possess cytotoxicities in the low micromolar range against A2780, A2780cisR, and HEK293 cell lines. Although they do not show selectivity toward cancer cells, they do have the ability to overcome cisplatin resistance in the A2780cisR cell line. Binding studies performed on L-histidine and the 1−16 mer amyloid β-protein show that the both the ruthenium and gold centers can bind to histidine residues, suggesting that these complexes have the capability to bind to the RU2, AU1, and AU1′ binding sites on the nucleosome core particle.
■ EXPERIMENTAL SECTION
Materials. All commercially available starting materials were purchased from Sigma-Aldrich, TCI, ABCR and used without further purification. Ruthenium trichloride hydrate was purchased from precious metals online and used in the synthesis of the [Ru(pcymene)Cl 2 ] 2 dimer. 52 L-histidine was purchased from ABCR and the 1−16 β-amyloid peptide (H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-GlyTyr-Glu-Val-His-His-Gln-Lys−OH) was purchased as a trifluoroacetate salt from Bachem. Dichloromethane was purified and degassed using a PureSolv solvent purification system (Innovative Technology INC) prior to use. Reactions were monitored via thin-layer chromatography carried out on silica plates (Merck 5554) and visualized under UV radiation (254 nm). Flash column chromatography was conducted in the normal phase on a CombiFlash-EZ prep machine installed with prepacked Luknova columns and the stated eluent system. S y n t h e s i s . G e n e r a l P r o c e d u r e o f 1 a − 1 d . 4 -(Diphenylphosphino)benzoic acid (1 equiv) and EDCI (1.3 equiv) were dissolved in dry CH 2 Cl 2 (3 mL) and stirred under N 2 at room temperature for 1 h. The solution was added dropwise to a solution of the appropriate ethylene glycol (1.5 equiv) and DMAP (0.5 equiv) in dry CH 2 Cl 2 (2 mL), and the reaction was stirred under N 2 at room temperature for 21 h. The reaction mixture was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification was achieved via flash column chromatography using an eluent system of C 6 H 14 / EtOAc and the product was isolated as a colorless oil.
Compound 1a. According to the general procedure, 4-(diphenylphosphino)benzoic acid (0.300 g, 0.979 mmol, 1 equiv), EDCI (0.244 g, 1.273 mmol, 1.3 equiv), tetraethylene glycol (0.285 g, General Procedure of 2a−2d. The appropriate monophosphine ligand (1 equiv) and freshly prepared AuCl(tht) 53 (1 equiv) were dissolved in CH 2 Cl 2 (10 mL) and stirred under N 2 and rt for 18 h. The reaction mixture was concentrated to 1 mL under reduced pressure and was purified via flash column chromatography using General Procedure for 3a−3d. 4-(Diphenylphosphino)benzoic acid (1.2 equiv) and EDCI (1.5 equiv) were dissolved in dry CH 2 Cl 2 (2 mL) and stirred under N 2 at room temperature for 1 h. The solution was added to a solution of the appropriate monophosphine gold(I) complex (1 equiv) and DMAP (0.5 equiv) in dry CH 2 Cl 2 (3 mL), and the reaction mixture was stirred under N 2 at room temperature for 20 h. The reaction mixture was washed with brine (40 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification was achieved via flash column chromatography using an eluent system of CH 2 Cl 2 /CH 3 OH. The product was washed with pentane (3 × 25 mL) and isolated as a cream oil. 4300 cells/well) and preincubated for 24 h. Stock solutions of compounds were prepared in DMSO and were rapidly diluted in a medium. The solutions were sequentially diluted to give a final DMSO concentration of 0.5% and a final compound concentration range (0−200 μM). Cisplatin and RAPTA-C were tested as positive (0−100 μM) and negative (200 μM) controls, respectively. The compounds were added to the preincubated 96-well plates in 100 μL aliquots, and the plates were incubated for a further 72 h. MTT (20 μL, 5 mg/mL in Dulbecco's phosphate buffered saline) was added to the cells, and the plates were incubated for a further 4 h. The culture medium was aspirated, and the purple formazan crystals, formed by the mitochondrial dehydrogenase activity of vital cells, were dissolved in DMSO (100 μL/well). The absorbance of the resulting solutions, directly proportional to the number of surviving cells, was quantified at 590 nm using a SpectroMax M5e multimode microplate reader (using SoftMax Pro software, version 6.2.2). The percentage of surviving cells was calculated from the absorbance of wells corresponding to the untreated control cells. The reported IC50 values are based on the means from two independent experiments, each comprising four tests per concentration level. Mass Spectrometry Binding Studies. Binding Studies of 4b with L-Histidine. Complex 4b was incubated under agitation with Lhistidine for 2 h in a 1:1 complex−amino acid ratio in unbuffered solution (98% Milli-Q water, 2% DMSO) at 310 K. The samples were diluted first in millQ water (factor 100) and then in CH 3 OH/ HCOOH (0.1% HCOOH in CH 3 OH) by a factor of 10.
Inorganic Chemistry
Binding Studies of 4a and 4d with 1−16-mer β-Amyloid Peptide. Complex 4a or 4d was incubated under agitation with the 16-mer β-amyloid protein for 2 h in a 1:3 complex−peptide ratio in unbuffered solution (98% Milli-Q, 2% DMSO) at 310 K. The samples were diluted first in millQ water (factor 100) and then in CH 3 OH/ HCOOH (0.1% HCOOH in CH 3 OH) by a factor of 10.
Xevo G2-S QTOF. Routine analyses were conducted on a Xevo G2-S QTOF mass spectrometer coupled to the Acquity UPLC Class Binary Solvent manager and BTN sample manager (Waters, Corporation, Milford, MA). The sample manager system temperature was maintained at 10°C, and the injection volume was 2 μL. Mass spectrometer detection was operated in positive ionization using the ZSpray dual-orthogonal multimode ESI/APCI/ESCi source. The TOF mass spectra were acquired in the resolution mode over the range of m/z 50−1200 at an acquisition rate of 0.036 s/spectra. The instrument was calibrated using a solution of sodium formate (0.01 mg/L in isopropanol/H 2 O 90:10) . A mass accuracy better than 5 ppm was achieved using a Leucine Enkephalin solution as lock-mass (200 pg/mL in ACN/H 2 O (50:50)) infused continuously using the LockSpray source. Source settings were as follows: cone, 25 V; capillary, 3 kV, source temperature, 150°C; desolvation temperature, 500°C, cone gas, 10 L/h, desolvation gas, 500 L/h. Data were processed using MassLynx 4.1 software and QuanLynx application for quantification.
LTQ Orbitrap FTMS. Mass spectrometry analyses were performed on a LTQ Orbitrap FTMS instrument (LTQ Orbitrap Elite FTMS, Thermo Scientific, Bremen, Germany) operated in the positive mode coupled with a robotic chip-based nano-ESI source (TriVersa Nanomate, Advion Biosciences, Ithaca, NY, United States). A standard data acquisition and instrument control system was utilized (Thermo Scientific), whereas the ion source was controlled by Chipsoft 8.3.1 software (Advion BioScience). Samples were loaded onto a 96-well plate (Eppendorf, Hamburg, Germany) within an injection volume of 5 μL. The experimental conditions for the ionization voltage was +1.4 kV, and the gas pressure was set at 0.30 psi. The temperature of ion transfer capillary was 275°C and the Slens value was settled at 67%.. FTMS spectra were obtained in the 200−2000 m/z range in the reduced profile mode with a resolution set to 120 000. In all spectra, one microscan was acquired with a maximum injection time value of 1000 ms. For CID, ETD and HCD analysis, each precursor ion was isolated with a width window of 8. Normalized collision energies for CID and HCD fragmentation were 30 and 18%, respectively. A total of 100 scans each consisting of 10 μscans were acquired in reduced profile mode and averaged. ETD reaction time was set at 180 ms.
General Input Apm 2 s Parameters. Experimental MS were exported as .txt files before being dropped into the Apm 2 s tool. 46, 51 Protons (+1 to +5), modifiable charge (+1 to +5), and metal adduct (C 56 H 58 AuO 7 P 2 Ru) in the different boxes of "List of groups". Zone widths were selected based of the Ru expected isotopic pattern (−6.5 to 8.5), and the common zone parameter was fixed "as second". Minimal similarity was set at 70%, max results at 500, and best result range at 0. b, y, and b/y (internal fragments) fragment ions were selected for the CID experiments, whereas c, z, and c/z were chosen for ETD.
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